Loading...

Aladdin Healthcare Technologies SE

NMI.DE•XETRA
Healthcare
Medical - Healthcare Information Services
€0.02
€0.00(0.00%)

Aladdin Healthcare Technologies SE (NMI.DE) Stock Overview

Explore Aladdin Healthcare Technologies SE’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap206.2K
P/E Ratio-0.22
EPS (TTM)N/A
ROE0.55%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

NMI.DE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Aladdin Healthcare Technologies SE (NMI.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.22 and a market capitalization of 206.2K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NMI.DEStats details for NMI.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NMI.DEAnalyst Recommendations details for NMI.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.

CEO

Wade Menpes-Smith

Employees

3

Headquarters

Unter den Linden 10, Berlin

Founded

2020

Frequently Asked Questions

;